We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Corbus Pharmaceuticals announced a restructuring of its workforce designed to reallocate capital to certain clinical and preclinical programs. The restructuring will result in a reduction of its workforce by 54%.
Corbus Pharmaceuticals said that anabasum achieved the primary endpoint of a Phase II study in patients with cystic fibrosis, with the experimental drug displaying an acceptable safety and tolerability profile at all examined doses with no serious or seve